Jyri Lommi

ORCID: 0000-0002-8125-5499
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cardiac Valve Diseases and Treatments
  • Cardiovascular Function and Risk Factors
  • Transplantation: Methods and Outcomes
  • Heart Failure Treatment and Management
  • Research in Social Sciences
  • Mechanical Circulatory Support Devices
  • Viral Infections and Immunology Research
  • Renal Transplantation Outcomes and Treatments
  • Lipoproteins and Cardiovascular Health
  • Cardiac Imaging and Diagnostics
  • Viral-associated cancers and disorders
  • Acute Myocardial Infarction Research
  • Protease and Inhibitor Mechanisms
  • Eosinophilic Disorders and Syndromes
  • Cardiac Structural Anomalies and Repair
  • Cardiomyopathy and Myosin Studies
  • Diet and metabolism studies
  • Cholesterol and Lipid Metabolism
  • Polyomavirus and related diseases
  • Coronary Interventions and Diagnostics
  • Cytomegalovirus and herpesvirus research
  • Herpesvirus Infections and Treatments
  • Cardiac Arrhythmias and Treatments
  • Cardiovascular and exercise physiology
  • Congenital heart defects research

Helsinki University Hospital
2012-2024

University of Helsinki
2004-2024

Hospital Universitario Virgen de la Arrixaca
2024

Instituto de Salud Carlos III
2022

Instituto de Investigación Biomédica de Málaga
2022

Lung Institute
1998-2021

Herttoniemi Hospital
2004-2008

Wihuri Research Institute
2006

Hospital District of Helsinki and Uusimaa
2005

Kainuun keskussairaala
1994-1995

Background— Giant-cell myocarditis often escapes diagnosis until autopsy or transplantation and has defied proper treatment trials for its rarity deadly behavior. Current therapy rests on multiple-drug immunosuppression but prognostic influence remains poorly known. We set out to analyze (1) our experience in diagnosing giant-cell (2) the outcome of patients combined immunosuppression. Methods Results— reviewed histories, diagnostic procedures, details treatment, 32 consecutive with...

10.1161/circheartfailure.112.969261 article EN Circulation Heart Failure 2012-11-14

Aims In aortic stenosis (AS), left ventricular (LV) hypertrophy is considered a compensatory response helping maintain systolic function. Recent research in experimental AS suggests, however, that LV not necessary to sustain contractions but may fact be maladaptive. The present work aimed clarify the role of AS-related heart failure (HF) man.

10.1093/eurheartj/ehi290 article EN European Heart Journal 2005-04-28

10.1016/0735-1097(96)00214-8 article EN publisher-specific-oa Journal of the American College of Cardiology 1996-09-01

Aortic stenosis (AS) is characterized by extensive remodelling of the valves, including infiltration inflammatory cells, extracellular matrix degradation, and fibrosis. The molecular mechanisms behind this adverse have remained obscure. In article, we study whether cathepsin G, an angiotensin II (Ang II)-forming elastolytic enzyme, contributes to progression AS.Stenotic aortic valves (n = 86) control 17) were analysed for transforming growth factor-beta1 (TGF-beta1), collagens I III with...

10.1093/eurheartj/ehi706 article EN European Heart Journal 2006-01-09

To investigate the possible role of elastolytic cathepsins S, K, and V their endogenous inhibitor cystatin C in adverse extracellular matrix remodeling stenotic aortic valves.Stenotic valves were collected at valve replacement surgery control cardiac transplantations. The expression was studied by conventional real-time polymerase chain reaction immunohistochemistry. Total cathepsin activity quantified a fluorometric microassay. When compared with valves, showed increased mRNA (P<0.05 for...

10.1161/01.atv.0000228824.01604.63 article EN Arteriosclerosis Thrombosis and Vascular Biology 2006-05-26

Background: Cancer is currently one of the most important factors affecting long-term health and survival heart transplant patients.Material methods: We calculated standardized incidence ratios (SIR) for different cancer sites cancer-specific mortality ratio (SMR) by linking a cohort 479 adult recipients transplanted in 1985–2014 (4491.6 person-years follow-up) with data from national Finnish Registry until end 2015, Statistics Finland's registry causes death.Results: A total 267 cancers...

10.1080/0284186x.2019.1580385 article EN Acta Oncologica 2019-03-01
Luís R. Lopes Maria Angela Losi Nabeel Sheikh Cécile Laroche Philippe Charron and 95 more Juan R. Gimeno Juan Pablo Kaski Aldo P. Maggioni Luigi Tavazzi Eloisa Arbustini Dulce Brito Jelena Čelutkienė Albert Hagège Aleš Linhart Jens Mogensen José Manuel García‐Pinilla Tomás Ripoll‐Vera Hubert Seggewiß Eduardo Villacorta Alida L.P. Caforio Perry Elliott Chris P Gale Branko Beleslin Andrzej Budaj Ovidiu Chioncel Nikolaos Dagres Nicolas Danchin David Erlinge Jonathan Emberson Michael Glikson Alastair Gray Meral Kayıkçıoğlu Aldo P. Maggioni Klaudia Vivien Nagy Aleksandr Nedoshivin Anna-Sonia Petronio Jolien Roo Hesselink Lars Wallentin Uwe Zeymer Alida L.P. Caforio Juan R. Gimeno Philippe Charron Perry Elliott Juan Pablo Kaski Aldo P. Maggioni Luigi Tavazzi Michał Tendera С. М. Комиссарова Н. Н. Чакова S. S. Niyazova Aleš Linhart Petr Kuchynka T Palecek Jana Podzimková Marek Fikrle Eneida R. Nemecek Henning Bundgaard Jacob Tfelt‐Hansen Juliane Theilade Jens Jakob Thune Å.B. Axelsson Jens Mogensen F.L. Henriksen Thomas Morris Hey Søren K. Nielsen Lars Videbæk Simon Andreasen H Arnsted Anas M. Saad Muzaffar Ali Jyri Lommi Tiina Heliö M S Nieminen Olivier Dubourg Nicolas Mansencal Murat Nihat Arslan V. Siam Tsieu Thibaud Damy Aziz Guellich Soulef Guendouz Claire Marie Tissot Aurélia Lamine Stéphane Rappeneau Albert Hagège Michel Desnos A Bachet M. Hamzaoui Philippe Charron R Isnard L. Legrand Carole Maupain Estelle Gandjbakhch Mathieu Kerneïs J.F. Pruny Anna Bauer Barbara Pfeiffer S B Felix Marcus Dörr Sabine Kaczmarek Kristin Lehnert

The interaction between common cardiovascular risk factors (CVRF) and hypertrophic cardiomyopathy (HCM) is poorly studied. We sought to explore the relation CVRF clinical characteristics of patients with HCM enrolled in EURObservational Research Programme (EORP) Cardiomyopathy registry.1739 were hypertension (HT), diabetes (DM), body mass index (BMI), traits was analysed. Analyses stratified according presence or absence a pathogenic variant sarcomere gene. prevalence HT, DM, obesity (Ob)...

10.1093/ehjqcco/qcac006 article EN cc-by European Heart Journal - Quality of Care and Clinical Outcomes 2022-02-04

Cardiac allograft vasculopathy is characterized by increased coronary intimal thickness and a leading cause of death in heart transplant (HTx) recipients despite the routine use statins. The experience with inhibitors proprotein convertase subtilisin-kexin type 9 HTx limited. Our hypothesis was that lowering cholesterol 9inhibitor evolocumab would reduce these patients without compromising safety.

10.1016/j.jchf.2024.04.026 article EN cc-by JACC Heart Failure 2024-06-26

10.1016/s0002-9149(99)80304-x article EN The American Journal of Cardiology 1995-11-01

Increased activity of pro-inflammatory cytokines in the circulation has been observed many, though not all, patients with congestive heart failure. To identify predictors cytokine activation failure, we assessed relationship peripheral and hepatic venous to central haemodynamics, neuroendocrine status intermediary metabolism moderate or severe failure.Concentrations tumour necrosis factor-alpha, soluble factor-receptor II interleukin 6 were measured from plasma 58 adult cardiac patients,...

10.1093/oxfordjournals.eurheartj.a015142 article EN European Heart Journal 1997-10-02

Lommi J, Koskinen P, Näveri M, Härkönen Kupari M (Helsinki University Central Hospital, Helsinki, Finland). Heart failure ketosis. J Intern Med 1997; 242 : 231–8. Objective To assess whether blood ketone bodies are increased in congestive heart (CHF). Methods Thirteen patients with CHF and 11 cardiac without took part the study. Blood acetoacetate b–hydroxybutyrate levels pertinent metabolic hormonal milieu were measured during 20 h fast after 2 glucose infusion. Results The averaged body...

10.1046/j.1365-2796.1997.00187.x article EN Journal of Internal Medicine 1997-09-01

The pathogenesis of aortic valve stenosis (AS) is characterized by the accumulation LDL-derived cholesterol in diseased valves. Since LDL particles also contain plant sterols, we investigated whether sterols accumulate lesions. Serum samples were collected from 82 patients with severe AS and 12 control subjects. Aortic valves obtained a subpopulation 21 undergoing surgery 10 controls. valvular total noncholesterol measured gas-liquid chromatography. Noncholesterol including both precursors...

10.1194/jlr.m800058-jlr200 article EN cc-by Journal of Lipid Research 2008-04-09

Background: Ischemia-reperfusion injury may compromise the short-term and long-term prognosis after heart transplantation. Experimental studies show that simvastatin administered to organ donor is vasculoprotective inhibits cardiac allograft ischemia-reperfusion injury. Methods: Eighty-four multiorgan donors were randomly assigned receive 80 mg of (42 donors) via nasogastric tube declaration brain death upon acceptance as a donor, or no donors). The primary efficacy end point was...

10.1161/circulationaha.119.039932 article EN Circulation 2019-07-29

10.1016/s0735-1097(96)00214-8 article EN Journal of the American College of Cardiology 1996-09-01

AimsIn aortic stenosis (AS), adverse remodelling of the valves may depend on altered local regulation pro- and antifibrotic systems. We have recently shown that angiotensin-converting enzyme (ACE), which generates profibrotic angiotensin II inactivates bradykinin (BK), is upregulated in stenotic valves. Here, we analyse expression neutral endopeptidase (NEP), another BK-degrading enzyme, BK receptors AS.

10.1093/eurheartj/ehm129 article EN European Heart Journal 2007-05-15

The use of venoarterial extracorporeal membrane oxygenation in cardiogenic shock keeps increasing, but its cost-utility is unknown.We studied retrospectively the a five-year cohort consequent patients treated due to refractory or cardiac arrest transplant centre 2013-2017. In our centre, considered for all potentially eligible heart transplantation, and selected postcardiotomy patients. We assessed costs index hospitalization one-year hospital costs, patients' health-related quality life...

10.1177/2048872619900090 article EN European Heart Journal Acute Cardiovascular Care 2020-01-31

Abstract Background Cardiac allograft vasculopathy (CAV) is characterized by diffuse thickening of the arterial intima. Statins reduce incidence CAV, but despite use statins, CAV remains one leading causes long‐term death after heart transplant. Inhibitors proprotein convertase subtilisin‐kexin type 9 (PCSK9) substantially cholesterol levels have not been tested in transplant recipients. Methods The Cholesterol lowering with EVOLocumab to prevent cardiac Vasculopathy De‐novo recipients...

10.1111/ctr.13984 article EN Clinical Transplantation 2020-05-23

The influence of body posture on atrial sensing was examined in a single-lead VDD pacemaker 16 patients. At implantation, position searched for the floating bipolar sensor to obtain an adequate signal amplitude. After 1-12 months signals were measured by programming sensitivity five postures: supine, sitting, and standing lying right left sides. group mean amplitudes equal all postures, comparable supine value (1.01 +/- 0.51 mV). However, values within each individual varied considerably...

10.1111/j.1540-8159.1996.tb03332.x article EN Pacing and Clinical Electrophysiology 1996-03-01
Coming Soon ...